Hyperleukocytosis and leukostasis: management of a medical emergency

References

• Majhail NS. Lichtin a acute leukemia with a very high leukocyte count: confronting a medical emergency. Clev Clin J Med. 2004;71(8):633–637.
   PubMed Web of Science ®Google Scholar
• Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute. Leukemia Ther Apher. 2002;6(1):15–23.
   PubMedGoogle Scholar
• Hoelzer D, Thiel E, Buchner A, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123–131.
   PubMed Web of Science ®Google Scholar
• Cukierman T, Gatt ME, Libster D, et al. Chronic lymphocytic leukaemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma. 2002 Sep;43(9):1865–1868.
   PubMed Web of Science ®Google Scholar
• Resende LSR, Coradazzi AL, Rocha-Junior C, et al. Sudden bilateral deafness from hyperleukocytosis in chronic myeloid leukaemia. Acta Haematol. 2000;104:46–49.
   PubMed Web of Science ®Google Scholar
• Lichtman MA, Rome JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood. 1982;60(2):279–283.
   PubMed Web of Science ®Google Scholar
• Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol. 1985;3(12):1590–5rcd.
   PubMed Web of Science ®Google Scholar
• Eguiguren JM, Schell MJ, Crist WM, et al. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocitosis. Blood. 1992;79:871–875.
   PubMed Web of Science ®Google Scholar
• Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18.
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987;5(9):1364–1372.
   PubMed Web of Science ®Google Scholar
• Blum W. Porcu P Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome semin. Thromb Hemost. 2007;33(4):350–354.
   Web of Science ®Google Scholar
• Appelbaum FR, Kopecky KJ. Long-term survival after chemotherapy for acute myeloid leukaemia. Cancer Suppl. 1997;80:2199–2204.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypes. Cancer Res. 1998;58:4173–4179.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukaemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a southwest oncology group study. Blood. 2002;100:3869–3876.
   PubMed Web of Science ®Google Scholar
• Chen CC, Yang CF, Yang MH, et al. Pre-treatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukaemia. Ann Oncol. 2005;16:1366–1373.
   PubMed Web of Science ®Google Scholar
• Gupta V, Chun K, Yi Q, et al. Disease biology rather than age is the most important determination of survival of patients > 60 years with acute myeloid leukaemia treated with uniform intensive therapy. Cancer. 2005;103:2082–2090.
   PubMed Web of Science ®Google Scholar
• Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukemia: a single-center retrospective study and review of literature. Leuk Res. 2008;32(8):1221–1227.
   PubMed Web of Science ®Google Scholar
• Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukaemia. Leuk Lymphoma. 2006;47:1245–1252.
   PubMed Web of Science ®Google Scholar
• Flasshove M, Meusers P, Schütte J, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute leukaemia. Ann Hematol. 2000;79:533–542.
   PubMed Web of Science ®Google Scholar
• Wahlin A, Markevarn B, Golovleva I, et al. Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Haematol. 2002;68:54–63.
   PubMed Web of Science ®Google Scholar
• Behringer B, Pitako JA, Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or non-curative treatment: a single-center retrospective study. Ann Hematol. 2003;82:381–389.
   PubMed Web of Science ®Google Scholar
• Van Buchen MA, Te Velde J, Willemze R, et al. Leukostasis, an underestimated cause of death in leukaemia. Blut. 1988;56(1):39–44.
   PubMedGoogle Scholar
• Takazoe K, Abe A, Kawamura T, et al. Persistent renal failure in acute myelomonocytic leukaemia: possible role of massive leukaemia infiltration in the renal interstitium. Nephron. 1996;73(4):728–729.
   PubMed Web of Science ®Google Scholar
• Tobelem G, Jacquillat C, Chastang C, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood. 1980 Jan;55(1):71–76.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Heinemann HO, Farhangi M, et al. Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med. 1969 Sep;47(3):351–366.
   PubMed Web of Science ®Google Scholar
• Lichtman MA, Heal J, Rowe JM. Hyperleukocytic leukemia: rheological and clinical features and management. Clin Haematol. 1987;1:725–746.
   Google Scholar
• Frankel DH, Larson RA, Lorincz AL, et al. Acral lividosis-a sign of myeloproliferative diseases. Hyperleukocytosis Syndrome in Chronic Myelogenous Leukemia arch dermatol. 1987;123:921–924.
   PubMedGoogle Scholar
• Würthner JU, Köhler G Behringer D Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases. Cancer. 1999;15;85(2):368–374.
   Web of Science ®Google Scholar
• Cohen Y, Amir G, Da’as N, et al. Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis. Am J Hematol. 2002;71:47–49.
   PubMed Web of Science ®Google Scholar
• Vernant JP, Brun B, Mannoni P, et al. Respiratory distress of hyperleukocytic graulocytic leukemias. Cancer. 1979 Jul;44(1):264–268.
   PubMed Web of Science ®Google Scholar
• McKee LC Jr, Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimora). 1974;53:463–478.
   PubMed Web of Science ®Google Scholar
• Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015 May 21;125(21):3246–3252.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Matsumoto T, Miura G, et al. HRCT findings of chest complications in patients with leukemia. Eur Radiol. 2002 Jun;12(6):1512–1522.
   PubMed Web of Science ®Google Scholar
• Potenza L, Luppi M, Morselli M, et al. Leukaemic pulmonary infiltrates in adult acute myeloid leukaemia: a high-resolution computerized tomography study. Br J Haematol. 2003 Mar;120(6):1058–1061.
   PubMed Web of Science ®Google Scholar
• Novotny JR, Müller-Beiβenhirtz H, Herget-Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol. 2005;74:501–510.
   PubMed Web of Science ®Google Scholar
• Piccirillo N, Laurenti L, Chiusolo P, et al. Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. Am J Hematol. 2009 Jun;84(6):381–382.
   PubMed Web of Science ®Google Scholar
• Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008 Dec;93(12):1877–1885.
   PubMed Web of Science ®Google Scholar
• Pession A, Masetti R, Gaidano G, et al. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. Adv Ther. 2011 Aug;28(8):684–697.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012 May;26(3):117–122.
   PubMed Web of Science ®Google Scholar
• Sissolak G, Hoffbrand AV, Mehta AB, et al. Interferon-alpha inducible 2ʹ-5ʹ oligoadenylate synthetase transcripts in lymphoid and myeloid leukemias. Leukemia. 1993 May;7(5):712–716.
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Bedringsaas SL, Ryningen A, et al. Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw. 2010 Sep;21(3):154–164.
   PubMed Web of Science ®Google Scholar
• Stucki A, Rivier AS, Gikic M, et al. Endotelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97(7):2121–2129.
   PubMed Web of Science ®Google Scholar
• Van Buchem MA, Hogendoorn PC, Bruijn JA, et al. Endothelial activation antigens in pulmonary leukostasis in leukemia. Acta Haematol. 1993;90(1):29–33.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Oyan AM, et al. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol. 2010 Mar;84(3):239–251.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Criscuolo M, Fianchi L, Dragonetti G, et al. Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. Expert Rev Hematol. 2016;9(2):197–208.
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012 Sep 6;120(10):1993–2002.
   PubMed Web of Science ®Google Scholar
• Myers TJ, Cole SR, Klatsky AU, et al. Respiratory failure due to pulmonary leukostasis following chemotherapy of acute non-lymphocytic leukemia. Cancer. 1983;53:1808–1813.
   Web of Science ®Google Scholar
• Dombret H, Hunault M, Faucher C, et al. Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils. Cancer. 1992;69:1356–1361.
   PubMed Web of Science ®Google Scholar
• Tryka AF, Godleski JJ, Fanta CH. Leukemic cell lysis pneumopathy after chemotherapy: a complication of treated myeloblastic leukemia. Cancer. 1982;50:2763–2770.
   PubMed Web of Science ®Google Scholar
• Grund FM, Armitage JO, Burns CP. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Int Med. 1977;137:1246–1247.
   PubMed Web of Science ®Google Scholar
• Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleukocytosis leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98:433–436.
   PubMed Web of Science ®Google Scholar
• Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfus Med Hemother. 2012 Aug;39(4):241–245.
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Tanaka T, Ohmori T, et al. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol. 2014 Aug 7;20(29):9699–9715.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001 Jun;42(1–2):67–73.
   PubMed Web of Science ®Google Scholar
• Thiébaut A, Thomas X, Belhabri A, et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000 Sep;79(9):501–506.
   PubMed Web of Science ®Google Scholar
• Powell BL, Gregory BW, Evans JK, et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia. 1991 Dec;5(12):1037–1042.
   PubMed Web of Science ®Google Scholar
• Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):457–460.
   PubMedGoogle Scholar
• Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177.
   PubMed Web of Science ®Google Scholar
• De Santis GC, De Oliveira LC, Romano LG, et al. Falcao RP.Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. Clin Apher. 2011;26(4):181–185.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Liseth K, Stamnesfet S, et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med. 2013 Dec;23(6):397–406.
   PubMed Web of Science ®Google Scholar
• Pham HP, Schwartz J. How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. Transfusion. 2015 Oct;55(10):2306–2311.
   PubMed Web of Science ®Google Scholar
• Vahdat L, Maslak P, Miller WH Jr,et al.Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.Blood.1994 Dec 1;84(11):3843–3849. Review.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 Feb 26;113(9):1875–1891.
   PubMed Web of Science ®Google Scholar
• Abla O, Khanani MF, Hitzler JK, et al. Complications of hyperleukocytosis and leukapheresis in pediatric acute leukemia. Blood. 2004;104(abstract):1963.
   Google Scholar
• Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis Transfusion. 2007;47:1843–1850.
   PubMed Web of Science ®Google Scholar
• Chang MC, Chen TY, Tang JL, et al. Ho HT.Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007 Nov;82(11):976–980.
   PubMed Web of Science ®Google Scholar
• Pastore F, Pastore A, Wittmann G, et al. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9(4):e95062.
   Web of Science ®Google Scholar
• Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014 Apr;38(4):460–468.
   PubMed Web of Science ®Google Scholar
• Sung L, Aplenc R, Alonzo TA, et al. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the children’s oncology group. Haematologica. 2012 Nov;97(11):1770–1773.
   PubMed Web of Science ®Google Scholar
• Kuruvilla JG, Greenwood MD, Hogge DE, et al. Outcome for patients with acute myelogenous leukemia and hyperleukocytosis requiring urgent leukapheresis at diagnosis. Blood. 2002;100(abstract):4598.
   Google Scholar
• Kuo KHM, Callum J, Brandwein J, et al. Management of hyperleukocytosis in acute myelogenous leukemia using hydroxyurea rather than leukapheresis. Blood (ASH Annual Meeting Abstracts). 2006;108:2007.
   Google Scholar